Retatrutide, an investigational triple hormone agonist, produced significant reductions in both A1c and weight in a phase 3 trial of people with type 2 diabetes (T2D), manufacturer Eli Lilly and ...

"Overall, this study highlights the potential benefit of a combined approach to actively reduce both BMI and HbA1c [A1c] in people living with T2D to further reduce the risk of complications and ...

Doctor weighing woman on scales. A larger percentage of weight loss regained after an intensive lifestyle intervention was positively associated with certain cardiometabolic risk factors in type 2 ...

Cardiovascular (CV) risk is elevated in people with type 2 diabetes (T2D), and diet can play an ameliorative role. Frankie B. Stentz, PhD, MS, of the University of Tennessee Health Science Center in ...

Eli Lilly reported study results Thursday that confirmed the "superior weight loss profile" of its next-gen obesity drug, retatrutide.

Improvement in QoL, other PROs seen for those who switched to tirzepatide after not achieving glycemic control on stable dose of dulaglutide.

This is a syndicated post stub. Renal and Urology News, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform ...